Balestracci Beatrice, Candido Giuseppe, Federici Lorenzo, Parretti Chiara, Tartaglia Riccardo, Lachman Peter, Bianco Alessandra, La Regina Micaela
Independent Researcher, 54023 Filattiera, Italy.
Department of Engineering Sciences, Guglielmo Marconi University, 00193 Rome, Italy.
Healthcare (Basel). 2024 Dec 16;12(24):2541. doi: 10.3390/healthcare12242541.
: Large-scale vaccination was crucial to address the global COVID-19 pandemic and its associated health risks, including fatal and disabling diseases. However, there were significant challenges to be overcome to ensure the safe and effective implementation of the vaccination program. The aim of the present study was to assess patient safety threats related to the anti-COVID-19 large-scale vaccination process. : Between February and May 2021, we conducted a proper analysis to proactively identify risks and potential Failure Modes (FMs) in the COVID-19 vaccination process using the Failure Mode, Effects, and Criticality Analysis (FMECA) technique at an Italian Public Health Authority. A standardized risk scoring system was used to assess the severity, frequency, and detectability of events associated with potential failures. Criticalities were identified in both the preparatory and operational areas of the vaccination process, and several potential FMs were listed in descending order of risk score (Risk Priority Number, RPN) to ensure prioritization of interventions. : The most critical steps were found to be in the operational area rather than in the preparatory one. The highest RPNs were associated with failure or inadequate management of severe allergic reactions that can lead to serious harm and even death of the vaccinated person (RPN 60) and failure to keep updated vaccination teams' knowledge (RPN 36). : Ensuring patient safety and effective clinical risk management are crucial in mass vaccination campaigns. By prioritizing these aspects through collaboration with various stakeholders and implementing preventive measures, patient trust-on which vaccination campaign success relies-can be built and maintained.
大规模疫苗接种对于应对全球新冠疫情及其相关健康风险(包括致命和致残性疾病)至关重要。然而,要确保疫苗接种计划的安全有效实施,仍有重大挑战需要克服。本研究的目的是评估与新冠大规模疫苗接种过程相关的患者安全威胁。2021年2月至5月期间,我们在意大利一家公共卫生机构运用失效模式、影响及危害性分析(FMECA)技术,进行了一项恰当的分析,以主动识别新冠疫苗接种过程中的风险和潜在失效模式(FMs)。使用标准化风险评分系统评估与潜在故障相关事件的严重性、发生频率和可检测性。在疫苗接种过程的准备和操作区域均识别出了关键问题,并按照风险评分(风险优先数,RPN)从高到低列出了几种潜在的失效模式,以确保干预措施的优先级。结果发现,最关键的步骤存在于操作区域而非准备区域。最高的RPN与严重过敏反应的处理失败或不当有关,这可能导致接种者受到严重伤害甚至死亡(RPN 60),以及未能及时更新疫苗接种团队的知识(RPN 36)。在大规模疫苗接种活动中,确保患者安全和有效的临床风险管理至关重要。通过与各利益相关方合作,优先考虑这些方面并实施预防措施,可以建立并维持疫苗接种活动成功所依赖的患者信任。